Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 9, 2022
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
[ Wed, Mar 09th 2022
] - WOPRAI
Tue, March 8, 2022
[ Tue, Mar 08th 2022
] - WOPRAI
[ Tue, Mar 08th 2022
] - WOPRAI
[ Tue, Mar 08th 2022
] - WOPRAI
[ Tue, Mar 08th 2022
] - WOPRAI
[ Tue, Mar 08th 2022
] - WOPRAI
Paul Matteis Downgraded (BIIB) to Hold and Decreased Target to $223 on, Mar 8th, 2022
Paul Matteis of Stifel, Downgraded "Biogen Inc." (BIIB) to Hold and Decreased Target from $304 to $223 on, Mar 8th, 2022.
Paul has made no other calls on BIIB in the last 4 months.
There are 18 other peers that have a rating on BIIB. Out of the 18 peers that are also analyzing BIIB, 11 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Mohit Bansal of "Wells Fargo" Maintained at Hold with Decreased Target to $235 on, Friday, February 4th, 2022
- Evan Seigerman of "BMO Capital" Downgraded from Buy to Hold and Decreased Target to $238 on, Friday, February 4th, 2022
- Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $244 on, Thursday, January 20th, 2022
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
- Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
- Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
- Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $275 on, Thursday, December 23rd, 2021
- Cory Kasimov of "JP Morgan" Maintained at Hold with Decreased Target to $276 on, Tuesday, December 21st, 2021
- Brian Skorney of "Baird" Maintained at Hold with Decreased Target to $258 on, Tuesday, December 21st, 2021
- Salveen Richter of "Goldman Sachs" Initiated at Hold and Held Target at $271 on, Monday, December 6th, 2021
These are the ratings of the 7 analyists that currently disagree with Paul
- Brian Abrahams of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $248 on, Thursday, March 3rd, 2022
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $305 on, Monday, February 7th, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $330 on, Friday, February 4th, 2022
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $290 on, Friday, February 4th, 2022
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $300 on, Monday, January 24th, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022
- Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $350 on, Wednesday, December 22nd, 2021
